Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans

British Journal of Pharmacology

Volumn 160, Issue 6, 2010, Pages 1550-1560

  Sciorati, Clara ^a   Buono, Roberta ^b   Azzoni, Emanuele ^a,c   Casati, Silvana ^b   Ciuffreda, Pierangela ^b   D'Angelo, Grazia ^d   Cattaneo, Dario ^b   Brunelli, Silvia ^a,c   Clementi, Emilio ^b,d  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d SCIENTIFIC INSTITUTE   (Italy)

Author keywords

inflammation; muscular dystrophy; nitric oxide; skeletal muscle regeneration

Indexed keywords

IBUPROFEN; ISOSORBIDE DINITRATE; NITRIC OXIDE; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; SARCOGLYCAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; INFLAMMATION; MOUSE; MUSCLE FUNCTION; MUSCLE INJURY; MUSCLE NECROSIS; MUSCLE REGENERATION; MUSCULAR DYSTROPHY; NONHUMAN; PRIORITY JOURNAL; STEM CELL; ANIMAL; GENETICS; KNOCKOUT MOUSE; METABOLISM; MUSCULAR DYSTROPHY, ANIMAL; PATHOPHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG SYNERGISM; IBUPROFEN; ISOSORBIDE DINITRATE; MICE; MICE, KNOCKOUT; MUSCULAR DYSTROPHY, ANIMAL; NITRIC OXIDE DONORS; SARCOGLYCANS; STEM CELLS;

EID: 77954045900     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00809.x     Document Type: Article

References (61)

1. Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC). 4th edn. Br J Pharmacol 158 (Suppl. 1 S1 S254.
2. Anderson JE (2000). A role for nitric oxide in muscle repair: nitric oxide-mediated activation of muscle satellite cells. Mol Biol Cell 11 : 1859 1874.
3. Archer JD, Vargas CC, Anderson JE (2006). Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort. FASEB J 20 : 738 740.
4. Barton ER, Morris L, Kawana M, Bish LT, Toursel T (2005). Systemic administration of L-arginine benefits mdx skeletal muscle function. Muscle Nerve 32 : 751 760.
5. Benabdellah F, Yu H, Brunelle A, Laprevote O, De La Porte S (2009). MALDI reveals membrane lipid profile reversion in MDX mice. Neurobiol Dis 36 : 252 258.
6. Betters JL, Long JH, Howe KS, Braith RW, Soltow QA, Lira VA et al. (2008). Nitric oxide reverses prednisolone-induced inactivation of muscle satellite cells. Muscle Nerve 37 : 203 209.
7. Bredt DS (1998). NO skeletal muscle derived relaxing factor in Duchenne muscular dystrophy. Proc Natl Acad Sci USA 95 : 14592 14593.
8. Brunelli S, Rovere-Querini P, Sciorati C, Manfredi AA, Clementi E (2007a). Nitric oxide: emerging concepts about its use in cell-based therapies. Expert Opin Investig Drugs 16 : 33 43.
9. Brunelli S, Sciorati C, D'Antona G, Innocenzi A, Covarello D, Galvez BG et al. (2007b). Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. Proc Natl Acad Sci USA 104 : 264 269.
10. Buckingham M, Bajard L, Chang T, Daubas P, Hadchouel J, Meilhac S et al. (2003). The formation of skeletal muscle: from somite to limb. J Anat 202 : 59 68.
11. Burdi R, Rolland JF, Fraysse B, Litvinova K, Cozzoli A, Giannuzzi V et al. (2009). Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: outcome of a large array of in vivo and ex vivo tests. J Appl Physiol 106 : 1311 1324.
12. Clementi E, Borgese N, Meldolesi J (2003). Interactions between nitric oxide and sphingolipids and the potential consequences in physiology and pathology. Trends Pharmacol Sci 24 : 518 523.
13. Colussi C, Mozzetta C, Gurtner A, Illi B, Rosati J, Straino S et al. (2008). HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci USA 105 : 19183 19187.
14. Cossu G, Sampaolesi M (2004). New therapies for muscular dystrophy: cautious optimism. Trends Mol Med 10 : 516 520.
15. Deigner HP, Haberkorn U, Kinscherf R (2000). Apoptosis modulators in the therapy of neurodegenerative diseases. Expert Opin Investig Drugs 9 : 747 764.
16. Deng B, Glanzman D, Tidball JG (2009). Nitric oxide generated by muscle corrects defects in hippocampal neurogenesis and neural differentiation caused by muscular dystrophy. J Physiol 587 : 1769 1778.
17. Dorchies OM, Wagner S, Buetler TM, Ruegg UT (2009). Protection of dystrophic muscle cells with polyphenols from green tea correlates with improved glutathione balance and increased expression of 67LR, a receptor for (-)-epigallocatechin gallate. Biofactors 35 : 279 294.
18. Duclos F, Straub V, Moore SA, Venzke DP, Hrstka RF, Crosbie RH et al. (1998). Progressive muscular dystrophy in alpha-sarcoglycan-deficient mice. J Cell Biol 142 : 1461 1471.
19. Emery AE (2002). The muscular dystrophies. Lancet 359 : 687 695.
20. Escolar D, Tesi-Rocha C, Clemens P, Iannaccone S, Pestronk A, Kuntz N et al. (2007). Immediate release oral pentoxifylline is poorly tolerated in Duchenne muscular dystrophy boys. Neuromuscul Disord 17 : 817.
21. Farrar H, Letzig L, Gill M (2002). Validation of a liquid chromatographic method for the determination of ibuprofen in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 780 : 341 348.
22. Ferdinand KC (2005). Isosorbide dinitrate and hydralazine hydrochloride: a review of efficacy and safety. Expert Rev Cardiovasc Ther 3 : 993 1001.
23. Filippin LI, Moreira AJ, Marroni NP, Xavier RM (2009). Nitric oxide and repair of skeletal muscle injury. Nitric Oxide 21 : 157 163.
24. Grounds MD, Torrisi J (2004). Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J 18 : 676 682.
25. Hnia K, Gayraud J, Hugon G, Ramonatxo M, De La Porte S, Matecki S et al. (2008). L-arginine decreases inflammation and modulates the nuclear factor-kappaB/matrix metalloproteinase cascade in mdx muscle fibers. Am J Pathol 172 : 1509 1519.
26. Huang P, Zhao XS, Fields M, Ransohoff RM, Zhou L (2009). Imatinib attenuates skeletal muscle dystrophy in mdx mice. FASEB J 23 : 2539 2548.
27. Jejurikar SS, Kuzon WM, Jr. (2003). Satellite cell depletion in degenerative skeletal muscle. Apoptosis 8 : 573 578.
28. Kobayashi YM, Rader EP, Crawford RW, Iyengar NK, Thedens DR, Faulkner JA et al. (2008). Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature 456 : 511 515.
29. Lai Y, Thomas GD, Yue Y, Yang HT, Li D, Long C et al. (2009). Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest 119 : 624 635.
30. Leroy S, Mosca A, Landre-Peigne C, Cosson MA, Pons G (2007). [Ibuprofen in childhood: evidence-based review of efficacy and safety]. Arch Pediatr 14 : 477 484.
31. Liu L, Stamler JS (1999). NO: an inhibitor of cell death. Cell Death Differ 6 : 937 942.
32. Lotsch J, Muth-Selbach U, Tegeder I, Brune K, Geisslinger G (2001). Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate. Br J Clin Pharmacol 52 : 387 398.
33. Mackey AL, Kjaer M, Dandanell S, Mikkelsen KH, Holm L, Dossing S et al. (2007). The influence of anti-inflammatory medication on exercise-induced myogenic precursor cell responses in humans. J Appl Physiol 103 : 425 431.
34. Manzur AY, Kuntzer T, Pike M, Swan A (2004). Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev : CD003725.
35. Manzur AY, Muntoni F (2009). Diagnosis and new treatments in muscular dystrophies. J Neurol Neurosurg Psychiatry 80 : 706 714.
36. Marques MJ, Luz MA, Minatel E, Neto HS (2005). Muscle regeneration in dystrophic mdx mice is enhanced by isosorbide dinitrate. Neurosci Lett 382 : 342 345.
37. Mendias CL, Tatsumi R, Allen RE (2004). Role of cyclooxygenase-1 and -2 in satellite cell proliferation, differentiation, and fusion. Muscle Nerve 30 : 497 500.
38. Mollace V, Muscoli C, Masini E, Cuzzocrea S, Salvemini D (2005). Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev 57 : 217 252.
39. Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, Sciorati C et al. (2003). Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 299 : 896 899.
40. Ontell M (1981). Muscle fiber necrosis in murine dystrophy. Muscle Nerve 4 : 204 213.
41. Percival JM, Anderson KN, Gregorevic P, Chamberlain JS, Froehner SC (2008). Functional deficits in nNOSmu-deficient skeletal muscle: myopathy in nNOS knockout mice. PLoS One 3 : e3387.
42. Pierno S, Nico B, Burdi R, Liantonio A, Didonna MP, Cippone V et al. (2007). Role of tumour necrosis factor alpha, but not of cyclo-oxygenase-2- derived eicosanoids, on functional and morphological indices of dystrophic progression in mdx mice: a pharmacological approach. Neuropathol Appl Neurobiol 33 : 344 359.
43. Pisconti A, Brunelli S, Di Padova M, De Palma C, Deponti D, Baesso S et al. (2006). Follistatin induction by nitric oxide through cyclic GMP: a tightly regulated signaling pathway that controls myoblast fusion. J Cell Biol 172 : 233 244.
44. Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds CR et al. (2002). A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet 11 : 263 272.
45. Radley HG, Davies MJ, Grounds MD (2008). Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment. Neuromuscul Disord 18 : 227 238.
46. Rando TA (2001). Role of nitric oxide in the pathogenesis of muscular dystrophies: a 'two hit' hypothesis of the cause of muscle necrosis. Microsc Res Tech 55 : 223 235.
47. Reutenauer J, Dorchies OM, Patthey-Vuadens O, Vuagniaux G, Ruegg UT (2008). Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy. Br J Pharmacol 155 : 574 584.
48. Sciorati C, Galvez BG, Brunelli S, Tagliafico E, Ferrari S, Cossu G et al. (2006). Ex vivo treatment with nitric oxide increases mesoangioblast therapeutic efficacy in muscular dystrophy. J Cell Sci 119 : 5114 5123.
49. Spencer MJ, Tidball JG (2001). Do immune cells promote the pathology of dystrophin-deficient myopathies? Neuromuscul Disord 11 : 556 564.
50. Stamler JS, Meissner G (2001). Physiology of nitric oxide in skeletal muscle. Physiol Rev 81 : 209 237.
51. Steen AE, Reeh PW, Geisslinger G, Steen KH (2000). Plasma levels after peroral and topical ibuprofen and effects upon low pH-induced cutaneous and muscle pain. Eur J Pain 4 : 195 209.
52. Takuma K, Phuagphong P, Lee E, Mori K, Baba A, Matsuda T (2001). Anti-apoptotic effect of cGMP in cultured astrocytes: inhibition by cGMP-dependent protein kinase of mitochondrial permeable transition pore. J Biol Chem 276 : 48093 48099.
53. Tanabe Y, Esaki K, Nomura T (1986). Skeletal muscle pathology in X chromosome-linked muscular dystrophy (mdx) mouse. Acta Neuropathol 69 : 91 95.
54. Thorsson O, Rantanen J, Hurme T, Kalimo H (1998). Effects of nonsteroidal antiinflammatory medication on satellite cell proliferation during muscle regeneration. Am J Sports Med 26 : 172 176.
55. Tsikas D (2000). Simultaneous derivatization and quantification of the nitric oxide metabolites nitrite and nitrate in biological fluids by gas chromatography/mass spectrometry. Anal Chem 72 : 4064 4072.
56. Voisin V, Sebrie C, Matecki S, Yu H, Gillet B, Ramonatxo M et al. (2005). L-arginine improves dystrophic phenotype in mdx mice. Neurobiol Dis 20 : 123 130.
57. Wagner KR (2008). Approaching a new age in Duchenne muscular dystrophy treatment. Neurother 5 : 583 591.
58. Wang G, Burczynski FJ, Hasinoff BB, Zhang K, Lu Q, Anderson JE (2009). Development of a nitric oxide-releasing analogue of the muscle relaxant guaifenesin for skeletal muscle satellite cell myogenesis. Mol Pharm 6 : 895 904.
59. Wehling M, Spencer MJ, Tidball JG (2001). A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol 155 : 123 131.
60. Wehling-Henricks M, Oltmann M, Rinaldi C, Myung KH, Tidball JG (2009). Loss of positive allosteric interactions between neuronal nitric oxide synthase and phosphofructokinase contributes to defects in glycolysis and increased fatigability in muscular dystrophy. Hum Mol Genet 18 : 3439 3451.
61. Zhao X, Chen D, Li K, Wang D (2005). Sensitive liquid chromatographic assay for the simultaneous determination of ibuprofen and its prodrug, ibuprofen eugenol ester, in rat plasma. Yakugaku Zasshi 125 : 733 737.